Dual therapy with anti-PD-1 and anti-TIGIT significantly improved survival, enhancing effector T cell function and reducing suppressive Tregs and tumor-infiltrating dendritic cells (TIDCs) (Hung et al., 2018). Here, TIGIT is linked to neoplasm.